BD Phoenix™ panels

Accurate and rapid susceptibility results

identification-mic-panels_RC_DS_IDS_0916-0021

identification-mic-panels_RC_DS_IDS_0916-0022

identification-panels_RC_DS_IDS_0916-0019

Overview
Applications
Products & Accessories
EIFU & Resources

false

Trusted performance

The BD Phoenix™ system provides on-panel doubling dilutions and built-in detection resistance, including CPO, MRSA, mecA, VRSA, VRE, ESBL, HLAR, and iMLSb*.

Ease of use

BD Phoenix™ panels can be stored at room temperature, are leak-resistant and do not require reagent additions post inoculation.

Emerging resistance detection

The BD Phoenix™ Emerge™ Gram-negative and Gram-positive panels offer 136 wells for susceptibility testing, allowing for additional antimicrobial dilutions that help provide the foundation for detecting emerging resistance.

Detecting Carbapenamase producing organisms (CPOs)

The BD Phoenix™ CPO detect test, offered on certain Gram-negative panels, provides information, including Ambler classification, to clinicians to help guide their treatment decisions.

Dual growth detection technology

BD Phoenix™ panels allow the BD Phoenix™ M50 instrument to determine growth using both an oxidation-reduction reaction and turbidity development, providing both rapid and accurate susceptibility results.

True doubling dilutions

The BD Phoenix™ system utilizes on-panel doubling dilutions of antimicrobial concentrations for determination of MIC results.

Multiple panel formats

BD Phoenix™ panels, which require no refrigeration and are leak resistant, are available in a variety of formats including identification-only and susceptibility-only, and in combination identification and susceptibility panels.

Largest number of wells per panel

With 136 wells dedicated to susceptibility testing, the BD Phoenix™ Emerge™ panel may allow for additional antimicrobial dilutions or additional drugs.

Resistance detection

The BD Phoenix™ system provides on-panel doubling dilutions of antimicrobials and built-in detection of resistance, including CPO, MRSA, mecA, VRSA, VRE, ESBL, HLAR, and iMLSb*.

*Depending on BD Phoenix™ panel type and organism identification.

Automated panel inoculation preparation

The BD Phoenix™ AP automated inoculation preparation instrument may help to reduce sample preparation workflow burdens, reducing total hands-on time per sample by 50% compared to manual BD Phoenix™ preparation and by an average of 20% compared to selected competitive products.^1-2

The BD Phoenix™ system offers identification-only panels and combination ID/AST panels, using 51 wells for identification substrates.
The instrument can provide rapid identification of most clinically significant Gram-negative and Gram- positive bacteria, as well as yeast.

The BD Phoenix™ system offers 85 wells for antimicrobial dilutions on standard AST-only panels and combination ID/AST panels, and 136 wells on the BD Phoenix™ Emerge™ panel.
The instrument can provide rapid susceptibility results for most clinically significant Gram-negative and Gram-positive bacteria.
The BD Phoenix™ system panels test for several resistance markers*such as**:
- Gram-positive bacteria
  - HLAR—High Level Aminoglycoside Resistant Enterococcus
  - iMLSb—Inducible Clindamycin Resistance
  - MRSA—based on Oxacillin Interpretation with Staphylococcus species
  - mecA - detection in mecA-mediated resistance Staphylococcus Aureus
  - BL-Staphylococcus ß-Lactamase (Nitrocefin-based test)
  - VRSA—Vancomycin-Resistant Staphylococcus Aureus
  - VRE—based on Vancomycin interpretation
- Gram-negative bacteria
  - CPO—Carbapenemase Producing Organism
  - ESBL—offered on Gram-negative panels and requires no additional disc diffusion or E-Test confirmation

* Depending on BD Phoenix™ panel type and organism identification.

The BD Phoenix™ CPO detect test, available on certain BD Phoenix™ Gram-negative panels, provides information, including Ambler classification, to help guide clinicians in their treatment decisions.
This test is available in two-panel configurations that allow microbiology labs to test for CPOs as part of routine susceptibility testing on BD Phoenix™ panels:
- 2-well configuration—provides detection of Carbapenemase-producing organisms in Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii
- 9-well configuration—provides detection of Carbapenemase-producing organisms and Ambler classification (A, B or D) in Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii
The BD Phoenix™ CPO detect test is currently the only phenotypic test on an automated AST system that provides CPO detection and Ambler classification.
On average, the BD Phoenix™ CPO detect test detects and classifies CPOs from isolated colonies within 6 to 11 hours**.

**BD internal studies—data on file